These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 32241872)

  • 1. Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity.
    Kotanides H; Sattler RM; Lebron MB; Carpenito C; Shen J; Li J; Surguladze D; Haidar JN; Burns C; Shen L; Inigo I; Pennello AL; Forest A; Chen X; Chin D; Sonyi A; Topper M; Boucher L; Sharma P; Zhang Y; Burtrum D; Novosiadly RD; Ludwig DL; Plowman GD; Kalos M
    Mol Cancer Ther; 2020 Apr; 19(4):988-998. PubMed ID: 32241872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity.
    Ho SK; Xu Z; Thakur A; Fox M; Tan SS; DiGiammarino E; Zhou L; Sho M; Cairns B; Zhao V; Xiong M; Samayoa J; Forsyth CM; Powers DB; Chao DT; Hollenbaugh D; Alvarez HM; Akamatsu Y
    Mol Cancer Ther; 2020 Apr; 19(4):1040-1051. PubMed ID: 31974274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity.
    Eskiocak U; Guzman W; Wolf B; Cummings C; Milling L; Wu HJ; Ophir M; Lambden C; Bakhru P; Gilmore DC; Ottinger S; Liu L; McConaughy WK; He SQ; Wang C; Leung CL; Lajoie J; Carson WF; Zizlsperger N; Schmidt MM; Anderson AC; Bobrowicz P; Schuetz TJ; Tighe R
    JCI Insight; 2020 Mar; 5(5):. PubMed ID: 32161196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement.
    Gaspar M; Pravin J; Rodrigues L; Uhlenbroich S; Everett KL; Wollerton F; Morrow M; Tuna M; Brewis N
    Cancer Immunol Res; 2020 Jun; 8(6):781-793. PubMed ID: 32273279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-CD137 Suppresses Tumor Growth by Blocking Reverse Signaling by CD137 Ligand.
    Kang SW; Lee SC; Park SH; Kim J; Kim HH; Lee HW; Seo SK; Kwon BS; Cho HR; Kwon B
    Cancer Res; 2017 Nov; 77(21):5989-6000. PubMed ID: 28923858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct CD137 costimulation of CD8 T cells promotes retention and innate-like function within nascent atherogenic foci.
    Xu MM; Ménoret A; Nicholas SE; Günther S; Sundberg EJ; Zhou B; Rodriguez A; Murphy PA; Vella AT
    Am J Physiol Heart Circ Physiol; 2019 Jun; 316(6):H1480-H1494. PubMed ID: 30978132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibodies directed against the T-cell activation molecule CD137 (interleukin-A or 4-1BB) block human lymphocyte-mediated suppression of tumor xenografts in severe combined immunodeficient mice.
    Sabel MS; Conway TF; Chen FA; Bankert RB
    J Immunother; 2000; 23(3):362-8. PubMed ID: 10838665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T cell costimulation with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes.
    Martinez-Forero I; Azpilikueta A; Bolaños-Mateo E; Nistal-Villan E; Palazon A; Teijeira A; Perez-Chacon G; Morales-Kastresana A; Murillo O; Jure-Kunkel M; Zapata JM; Melero I
    J Immunol; 2013 Jun; 190(12):6694-706. PubMed ID: 23690480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD137 (4-1BB) costimulation of CD8
    Otano I; Azpilikueta A; Glez-Vaz J; Alvarez M; Medina-Echeverz J; Cortés-Domínguez I; Ortiz-de-Solorzano C; Ellmark P; Fritzell S; Hernandez-Hoyos G; Nelson MH; Ochoa MC; Bolaños E; Cuculescu D; Jaúregui P; Sanchez-Gregorio S; Etxeberria I; Rodriguez-Ruiz ME; Sanmamed MF; Teijeira Á; Berraondo P; Melero I
    Nat Commun; 2021 Dec; 12(1):7296. PubMed ID: 34911975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD137, an attractive candidate for the immunotherapy of lung cancer.
    Ye L; Jia K; Wang L; Li W; Chen B; Liu Y; Wang H; Zhao S; He Y; Zhou C
    Cancer Sci; 2020 May; 111(5):1461-1467. PubMed ID: 32073704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity.
    Compte M; Harwood SL; Erce-Llamazares A; Tapia-Galisteo A; Romero E; Ferrer I; Garrido-Martin EM; Enguita AB; Ochoa MC; Blanco B; Oteo M; Merino N; Nehme-Álvarez D; Hangiu O; Domínguez-Alonso C; Zonca M; Ramírez-Fernández A; Blanco FJ; Morcillo MA; Muñoz IG; Melero I; Rodriguez-Peralto JL; Paz-Ares L; Sanz L; Alvarez-Vallina L
    Clin Cancer Res; 2021 Jun; 27(11):3167-3177. PubMed ID: 33785484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4-1BB Agonism Combined With PD-L1 Blockade Increases the Number of Tissue-Resident CD8+ T Cells and Facilitates Tumor Abrogation.
    Qu QX; Zhu XY; Du WW; Wang HB; Shen Y; Zhu YB; Chen C
    Front Immunol; 2020; 11():577. PubMed ID: 32391001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of follicular dendritic cell networks by activated T cells: the role of CD137 signaling.
    Sun Y; Blink SE; Chen JH; Fu YX
    J Immunol; 2005 Jul; 175(2):884-90. PubMed ID: 16002686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.
    Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL
    Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12.
    Quetglas JI; Dubrot J; Bezunartea J; Sanmamed MF; Hervas-Stubbs S; Smerdou C; Melero I
    Mol Ther; 2012 Sep; 20(9):1664-75. PubMed ID: 22735380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion.
    Houot R; Goldstein MJ; Kohrt HE; Myklebust JH; Alizadeh AA; Lin JT; Irish JM; Torchia JA; Kolstad A; Chen L; Levy R
    Blood; 2009 Oct; 114(16):3431-8. PubMed ID: 19641184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells.
    Mardiana S; John LB; Henderson MA; Slaney CY; von Scheidt B; Giuffrida L; Davenport AJ; Trapani JA; Neeson PJ; Loi S; Haynes NM; Kershaw MH; Beavis PA; Darcy PK
    Cancer Res; 2017 Mar; 77(6):1296-1309. PubMed ID: 28082401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer.
    Luo F; Luo M; Rong QX; Zhang H; Chen Z; Wang F; Zhao HY; Fu LW
    J Immunother Cancer; 2019 Sep; 7(1):245. PubMed ID: 31511071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy.
    Liu G; Luo P
    Front Immunol; 2023; 14():1208788. PubMed ID: 37334375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer.
    Mikami H; Feng S; Matsuda Y; Ishii S; Naoi S; Azuma Y; Nagano H; Asanuma K; Kayukawa Y; Tsunenari T; Kamikawaji S; Iwabuchi R; Shinozuka J; Yamazaki M; Kuroi H; Ho SSW; Gan SW; Chichili P; Pang CL; Yeo CY; Shimizu S; Hironiwa N; Kinoshita Y; Shimizu Y; Sakamoto A; Muraoka M; Takahashi N; Kawa T; Shiraiwa H; Mimoto F; Kashima K; Kamata-Sakurai M; Ishikawa S; Aburatani H; Kitazawa T; Igawa T
    Cancer Immunol Res; 2024 Jun; 12(6):719-730. PubMed ID: 38558120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.